Ir para o conteúdo principal

Aadi Bioscience Inc (NASDAQ: WHWK) — Perfil da empresa, notícias e dados financeiros

Logo de Aadi Bioscience Inc
WHWK Aadi Bioscience Inc
Imagem de banner da empresa
Perfil da empresa

Aadi Bioscience Inc

Aadi Bioscience (NASDAQ:AADI) is a dynamic player in the biotechnology arena, focused on developing and commercializing precision therapies for genetically defined cancers. Their flagship product, FYARRO, is already approved for the treatment of advanced malignant PEComa, an ultra-rare cancer. Utilizing innovative nanotechnology, they aim to harness mTOR inhibitors' potential for broader oncology indications. The company is delving into various clinical trials to expand their drug's applicability across different tumor types characterized by TSC1 and TSC2 mutations and other alterations in the mTOR pathway. Aadi Bioscience is committed to transforming patients' lives through cutting-edge precision medicine, forging new paths in cancer treatment and giving hope to those battling these challenging conditions.

Resumo

Public USParticipação acionária
-Ano de fundação
53Funcionários
Pacific Palisades, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Aadi Bioscience Inc

  • FYARRO: An mTOR inhibitor approved for treating advanced malignant PEComa, targeting mTOR pathway-driven tumors for patients with limiting treatment options.
  • Advanced solid tumors studies: Investigations evaluating FYARRO's potential to benefit patients across multiple tumor types with mTOR-driven malignancies.
  • MLN0128 Development: A potent inhibitor, aiming to expand therapeutic applications and address mTOR pathway anomalies in diverse cancers.
  • PIK3CA Mutations Research: Projects focusing on addressing genetic mutations to refine precision therapies involving mTOR inhibitors.
  • Orphan Drug Designations: Initiatives to secure special status for rare disease treatments, ensuring fiscal support and regulatory advantages.
  • Clinical Collaborations: Partnerships with research bodies to optimize drug development and expand scientific understanding of mTOR pathways.

equipe executiva do Aadi Bioscience Inc

  • David J. LennonPresident, CEO & Director
  • Neil P. DesaiFounder & Director
  • Scott M. GiacobelloCFO, Treasurer, Investor Relations & Corporate Communications
  • Bryan BallChief Technical Operations Officer
  • David DornanChief Scientific Officer
  • Stephen M. RodinSenior VP of Legal & General Counsel
  • Margaret Han DuganChief Medical Officer

Comunicados recentes

O que a Aadi Bioscience Inc (WHWK) comunicou ao mercado, do mais recente para o mais antigo.

Principais indicadores financeiros

Resultados divulgados pela Aadi Bioscience Inc, em USD.

Cap. de mercado
177,6 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Aadi Bioscience Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
7,1 mi-114,4 mi-20,6 mi
26 mi-67,5 mi-63,7 mi
24,4 mi-71,9 mi-65,8 mi
15,2 mi-62,7 mi-60,5 mi